drugset / Trial / NCT00017472

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

NCT00017472 ↗

Phase 1 Completed 35 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have chronic lymphocytic leukemia, lymphocytic lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia.

Timeline

Start
2001-04
Primary completion
2006-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject apolizumab Monoclonal antibody — Intravenous